hotspot -WSS

hotspot

author：fashion 2025-09-03 11:59:31 - browse：123

Adam's take main illustration — Molly Ferguson/STAT

CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly acquired and costly treatment for myelofibrosis. I suspect the Swiss pharma giant’s previously stated plan to submit a marketing application to the Food and Drug Administration this year has been blocked.

I’m not just speculating wildly. It’s looking increasingly likely that the $3 billion purchase of MorphoSys to acquire pelabresib — a deal pushed hard by top Novartis executive strategist Ronny Gal over some internal dissent — has run into serious trouble just days after the closing.

On Sunday evening, Novartis Chief Medical Officer Shreeram Aradhye, speaking at the company’s ASCO investor event here in Chicago, offered this response to an analyst who asked about pelabresib.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： 6 solutions to address cancer drug shortages and others

WSS

What will Novo Nordisk's VC do with its influx of cash?

New oral drug delivery patch is modeled after octopus tentacles

CDC picks Alphabet's Verily for wasterwater surveillance contract

The Karikó problem: Lessons for funding basic research

Nobel honors Karikó and Weissman's enduring partnership

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Experts study whether long Covid risk adds up with each reinfection

United colonoscopy coverage change 'may cost lives,' doctors say

The United States is paying nearly triple for new Covid vaccines

Anesthesiologist group: stop taking Ozempic before surgery

6 solutions to address cancer drug shortages and others

Medical leaders decry Supreme Court decision on affirmative action

Trump pressured former Arizona governor to overturn 2020 election results: Sources

Medicare proposal to cover medical devices draws a mixed reaction

What will Novo Nordisk's VC do with its influx of cash?

knowledge

US recommends Americans reconsider traveling to China due to arbitrary law enforcement, exit bans

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

Lawsuit highlights wrinkle for disputes over surprise medical bills

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

RSV injection headlines need to be accurate for good uptake

entertainment

explore

hotspot

Wikipedia